SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc

Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc (“Jazz Pharmaceuticals” or the “Company”) (NASDAQ:JAZZ) concerning possible violations of federal securities laws.

On May 6, 2016, Jazz Pharmaceuticals acknowledged receipt of a subpoena from the U.S. Attorney’s Office for the District of Massachusetts in May 2016. According to the Company, the subpoena requested documents related to the Company’s “support of 501(c)(3) organizations that provide financial assistance to Medicare patients, and, for Xyrem, documents concerning our provision of financial assistance to Medicare patients.” Then on May 27, 2016, Bloomberg reported that Jazz Pharmaceuticals is one of three major drugmakers to disclose receipt of a subpoena as part of this expanding federal investigation. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/jazz-pharmaceuticals-jazz

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160527005775/en/